(Q33416593)

English

Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 July 2017

Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study (English)

1 reference

Europe PubMed Central

26 July 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

non-Hodgkin lymphoma

1 reference

based on heuristic

inferred from title

B-cell non-Hodgkin lymphoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Catherine Thieblemont

2

object named as

Catherine Thieblemont

1 reference

Europe PubMed Central

26 July 2017

object named as

Ian Flinn

4

0 references

8

object named as

Jason Westin

1 reference

Europe PubMed Central

26 July 2017

author name string

Anas Younes

1

1 reference

Europe PubMed Central

26 July 2017

Franck Morschhauser

3

1 reference

Europe PubMed Central

26 July 2017

Jonathan W Friedberg

5

1 reference

Europe PubMed Central

26 July 2017

Sandy Amorim

6

1 reference

Europe PubMed Central

26 July 2017

Benedicte Hivert

7

1 reference

Europe PubMed Central

26 July 2017

Jessica Vermeulen

9

1 reference

Europe PubMed Central

26 July 2017

Nibedita Bandyopadhyay

10

1 reference

Europe PubMed Central

26 July 2017

Ronald de Vries

11

1 reference

Europe PubMed Central

26 July 2017

Sriram Balasubramanian

12

1 reference

Europe PubMed Central

26 July 2017

Peter Hellemans

13

1 reference

Europe PubMed Central

26 July 2017

Johan W Smit

14

1 reference

Europe PubMed Central

26 July 2017

Nele Fourneau

15

1 reference

Europe PubMed Central

26 July 2017

Yasuhiro Oki

16

1 reference

Europe PubMed Central

26 July 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

17 July 2014

1 reference

Europe PubMed Central

26 July 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

26 July 2017

15

1 reference

Europe PubMed Central

26 July 2017

9

1 reference

Europe PubMed Central

26 July 2017

1019-1026

1 reference

Europe PubMed Central

26 July 2017

Cancer statistics, 2014

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970311-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Diffuse large cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970311-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Pathogenesis of human B cell lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970311-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Oncogenic CARD11 mutations in human diffuse large B cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970311-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970311-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970311-0

7 January 2021

based on heuristic

inferred from DOI database lookup

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970311-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970311-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of older patients with mantle-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970311-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970311-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970311-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970311-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970311-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970311-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970311-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970311-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Revised response criteria for malignant lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970311-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970311-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970311-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970311-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970311-0

7 January 2021

based on heuristic

inferred from DOI database lookup

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970311-0

7 January 2021

based on heuristic

inferred from DOI database lookup

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970311-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970311-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(14)70311-0

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33416593&oldid=1606660190"